NYSE · IQV

IQVIA Holdings Inc.

Healthcare · Medical - Diagnostics & Research

$266.42▼ 1.12% ($3.02)at close

As of 4:02 PM ET

52-week

$154.50$273.88

Market cap

$43.85B

P/E

What the market price implies · Reverse DCF

To support a price of $266.42, this model requires Stage 1 FCFF to grow by 4.92%/yr over the next 5 years, compounded annually.

Historical FCFF grew by 19.44%/yr over the past 10 years. The required annual growth rate is 14.52 percentage points lower.

Selected forecast · Base scenario

19.44%/yr · Stage 1 default · years 1–5

Annual overrides take precedence over the Stage 1 default.

Market-implied · Other assumptions held fixed

4.92%/yr · Stage 1 · years 1–5

Stage 1 growth is solved while Stage 2 growth, terminal growth, discount inputs, and annual overrides remain fixed. This is a model-implied requirement, not an analyst forecast.

Valuation

Recommended · Cash-flow DCF

Price used

$266.42

Estimated value / share

$555.15

Base scenario

This estimate is 108.37% above the price used.

USD · TTM ending 2026-06-30

Reported total debt includes capitalised leases (~1% of the total). They are excluded from net debt and from the WACC weights because rent is already charged inside operating income. The Net Debt shown here is therefore lower than the balance-sheet figure elsewhere on this page.

Stage 1 19.44% · Stage 2 10.69% · Discount rate 9.58%

Assumption scenarios, not statistical confidence intervals.

Method, dates & sources

Estimated from future free cash flow, discounted to its value today.

Price timestamp: Sep 18, 2026, 8:02 PM UTC
Financial statement period: TTM ending 2026-06-30
Data refreshed: Sep 19, 2026, 9:16 AM UTC · provider

Why this method?

FCFF is positive, stable, long-lived, and the business looks mature enough that a direct FCFF DCF can use historical cash flow as the anchor.

Is FCFF positive and has it been for 3+ consecutive years? 16 consecutive positive FCFF years are available.

Is FCFF stable (not swinging >30% year to year)? The largest recent FCFF swing is 26.9%.

Do you have 5+ years of positive FCFF history? 16 consecutive positive FCFF years are available.

Is the business model structurally similar to what it should be in 10 years? Revenue growth and margin behavior look mature enough for direct FCFF compounding.

Price vs Fundamentals

Why The Stock Is Moving

Fundamentals are supporting the moveHigh confidence

1Y Price: 40.07%Revenue (TTM): 8.17%FCF (TTM): 30%P/FCF: 18th pct

What changed

The stock rose 40.07% over the last year. Revenue grew 8.17% over the trailing twelve months. Operating margin moved from 13.87% to 13.57%. Free cash flow grew 30% over the trailing twelve months.

What the market seems to be pricing

The stock move broadly lines up with stronger business momentum, and the shares are still only around the 18th percentile of their historical P/FCF range.

What would invalidate this read

Operating margin is at 13.57%. Revenue grew 8.17% — this thesis depends on that trajectory holding. If revenue growth, margins, or free cash flow roll over while the stock keeps climbing, more of the move would be coming from multiple expansion than business progress.

Performance

Return analysis

Company profile

IQVIA Holdings Inc. is a premier global provider of sophisticated analytical insights, advanced technology solutions, and comprehensive clinical research services, catering to the life sciences industry across the Americas, Europe, Africa, and Asia-Pacific.

CEOAri Bousbib

SectorHealthcare

IndustryMedical - Diagnostics & Research

Employees94,000

IPO dateMay 9, 2013

https://www.iqvia.com

Market multiples

Forward P/E—

EV/EBITDA15.28

Enterprise value$52.94B

Stock splits

No stock splits recorded for this ticker.

Profitability & growth

Revenue growth8.74%

Gross margin (FY2025)26.28%▼8.6ppvs FY2024

Operating margin (FY2025)14.02%▼0.3ppvs FY2024

ROE23.01%▲1.4ppvs FY2025

Analyst consensus

RatingBuy

Target price$246.13▼7.62%

Buy

Hold

Sell

Analyst ratings tend to be lagging indicators. Use as one signal among many.

Earnings

Full quarter-by-quarter history of actuals vs estimates. Switch into compare mode to inspect one metric year-over-year.

Next report

Nov 3, 2026

Q4 FY26 · EPS est $3.25 · Revenue est $4.36B

View